Holen Sie sich die Stockscreener-App
19.69
6.78%
1.25
Vorhandelsmarkt:
19.50
-0.19
-0.96%
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
Why Dyne Therapeutics stock was a big winner on Wednesday - MSN
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday - Finviz
Dyne Therapeutics (DYN) Upgraded by Oppenheimer, Potential 50% Upside - GuruFocus
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Dyne Therapeutics: Why The $350M Public Offering Was Critical (NASDAQ:DYN) - Seeking Alpha
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
Oppenheimer Upgrades Dyne Therapeutics to Outperform From Perform, Adjusts PT to $40 From $11 - marketscreener.com
Dyne Therapeutics (DYN) Sees Upgrade and Potential Stock Upside - GuruFocus
Dyne Therapeutics Prices $350 Million Public Offering - marketscreener.com
Dyne Therapeutics prices $350 stock offering - MSN
Dyne Therapeutics Prices Upsized Public Offering Of 18.98 Mln Shares - Nasdaq
Dyne Therapeutics prices upsized public offering at $18.44 per share - Investing.com
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - The Manila Times
Dyne Therapeutics Announces Pricing of Upsized Public Offering of Common Stock Amounting to $350 Million - Quiver Quantitative
Dyne Therapeutics says co prices public offering at $18.44 per share - marketscreener.com
Dyne Therapeutics Says Co Prices Public Offering At $18.44 Per Share - TradingView
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock - GlobeNewswire Inc.
Why Dyne Therapeutics Stock Tanked on Tuesday - The Globe and Mail
Dyne Therapeutics (DYN) Navigates a Paradoxical Day: Positive Clinical Data Overshadowed by Dilution Fears - Markets Financial Content
Dyne Therapeutics stock tumbles on $300 million share offering By Investing.com - Investing.com Canada
Dyne Therapeutics stock tumbles on $300 million share offering - Investing.com
Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate - Finviz
Dyne to seek accelerated approval of DMD drug on Phase I/II data - Yahoo Finance
Dyne Therapeutics (DYN) Target Price Raised to $50 by Morgan Sta - GuruFocus
Dyne Therapeutics (DYN) Stock Sees Significant Drop - GuruFocus
Dyne Therapeutics' Recent DMD Study Data Further Validates Force Platform, Morgan Stanley Says - marketscreener.com
Dyne Therapeutics slides after unveiling $300 million stock offering - TradingView
Dyne Therapeutics (DYN) Stock Declines by Over 13% - GuruFocus
Dyne Therapeutics (DYN) Maintains Buy Rating with Price Target a - GuruFocus
Dyne Therapeutics (NASDAQ:DYN) Given "Buy" Rating at Chardan Capital - MarketBeat
Dyne Therapeutics stock price target raised to $23 by Bernstein on positive DMD data - Investing.com UK
HC Wainwright Has Bullish Forecast for DYN FY2029 Earnings - MarketBeat
Morgan Stanley Raises Price Target on Dyne Therapeutics to $50 From $46, Keeps Overweight Rating - marketscreener.com
Dyne Delivers In Duchenne Trial; Now Aims To ACHIEVE Myotonic Dystrophy Milestones - RTTNews
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets - Yahoo Finance
Dyne Therapeutics (DYN) Is Up 7.7% After DELIVER Trial Success and Accelerated Approval Plan – Has The Bull Case Changed? - Yahoo Finance
Why Dyne Therapeutics Stock Was Blasting Higher Today - Finviz
HC Wainwright & Co. Maintains Dyne Therapeutics (DYN) Buy Recommendation - Nasdaq
The Technical Signals Behind (DYN) That Institutions Follow - news.stocktradersdaily.com
Dyne Therapeutics (DYN): Assessing Valuation as DELIVER Trial Topline Data Approaches - Yahoo Finance
Dyne Therapeutics launches $300 million common stock offering - Investing.com
Dyne Therapeutics amends loan agreement, secures additional $50 million tranche By Investing.com - Investing.com South Africa
Dyne Therapeutics Amends Loan Agreement for $50 Million - TipRanks
Dyne Therapeutics Launches $300 Million Public Offering; Shares Drop After Hours - marketscreener.com
Dyne Therapeutics amends loan agreement, secures additional $50 million tranche - Investing.com
Dyne Therapeutics launches $300 million common stock offering By Investing.com - Investing.com Canada
Dyne Therapeutics Announces Proposed Public Offering of Common Stock - The Manila Times
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Dyne Therapeutics announces proposed public offering of common stock - marketscreener.com
Dyne Therapeutics (Nasdaq: DYN) announces proposed $300M stock sale with $45M option - Stock Titan
Dyne Therapeutics stock price target raised to $50 from $46 at Morgan Stanley - Investing.com Canada
Why Is Dyne Therapeutics Stock Surging Monday?Dyne Therapeutics (NASDAQ:DYN), Sarepta Therapeutics (NASDAQ:SRPT) - Benzinga
DYN: DYNE-251 showed significant dystrophin gains and functional improvements in DMD, supporting accelerated approval plans - TradingView
Baird reiterates Outperform rating on Dyne Therapeutics stock, citing positive DMD data - Investing.com Canada
Dyne Therapeutics (NASDAQ:DYN) Shares Gap Up Following Analyst Upgrade - MarketBeat
HC Wainwright & Co. Raises Price Target for Dyne Therapeutics (D - GuruFocus
Transcript : Dyne Therapeutics, Inc.Special Call - marketscreener.com
Dyne Therapeutics rises after positive data for its muscle wasting drug - TradingView
HC Wainwright Forecasts Strong Price Appreciation for Dyne Therapeutics (NASDAQ:DYN) Stock - MarketBeat
Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular DystrophySlideshow (NASDAQ:DYN) 2025-12-08 - Seeking Alpha
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):